Monitor the EGM vote outcome on October 7, 2026, for any signal of shareholder dissent, but this is a routine governance matter with no expected impact on operations or stock price.
GMAB drugs
GMAB drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Sep 8 $33.53entry
- T+1 · 2mo ago −1.46%α −1.00% · $33.04
- T+5 · 2mo ago −2.62%α −1.96% · $32.65
- T+20 · 6w ago +12.73%α +10.77% · $37.80
- T+49 · todayOpen
- T+60 · in 15d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Genmab A/S filed a 6-K convening an Extraordinary General Meeting on October 7, 2026, to seek shareholder approval of the Board of Directors' remuneration for 2026, which remains unchanged from 2024 and 2025. The proposal was withdrawn at the March 2026 AGM, prompting extensive shareholder outreach; the Board recalibrated the compensation peer group to an equal mix of U.S. and European companies but retained current fee levels and the service-based RSU structure. This is a routine governance matter with no material financial impact on the company's operations or fundamentals.
Key Facts
- Genmab is holding an EGM on October 7, 2026, to vote on Board remuneration for 2026.
- The remuneration proposal was withdrawn at the March 19, 2026 AGM, leading to shareholder outreach covering over 60% of share capital.
- The Board recalibrated the peer group from 13 U.S. and 7 European companies to an equal mix of 10 U.S. and 10 European companies.
- Annual base fees and share-based RSU remuneration remain unchanged from 2024 and 2025.
- The Board decided not to adjust remuneration levels despite considering reductions based on shareholder feedback.
Financial Impact
No material financial impact; director remuneration is a routine governance expense.
Risk Factors
- Potential shareholder dissent if the unchanged remuneration fails to gain majority support at the EGM.
- Continued governance scrutiny from proxy advisors and institutional investors may lead to future adjustments.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001434265-26-000116 |
| Document: gmab_20260908xex99d1.htm | 0001434265-26-000116 |
| Document: gmab_20260908xex99d3.htm | 0001434265-26-000116 |
| Document: gmab_20260908x6k.htm | 0001434265-26-000116 |
| Document: 0001434265-26-000116-index-headers.html | 0001434265-26-000116 |
| Document: 0001434265-26-000116-index.html | 0001434265-26-000116 |
| Document: 0001434265-26-000116.txt | 0001434265-26-000116 |
Track record
31 reports on GMAB
3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +91.28% at T+60 after the Aug 6, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $52.12 Now $51.57 −1.06% settles Dec 15
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 10, 20266d ago 6-K Neutral 2/10 Entry $53.87 Now $51.57 −4.27% settles Dec 10
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $54.07 Now $51.57 −4.62% settles Dec 9
- Nov 5, 202611d ago 6-K Neutral 5/10 Entry $52.74 Now $51.57 −2.22% settles Dec 4
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $52.74 Now $51.57 −2.22% settles Dec 4
- Oct 28, 202619d ago 6-K Bullish 6/10 Entry $57.29 Now $51.57 −9.98% settles Nov 25
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers